and the Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group
In the setting of acute myocardial infarction, patients with a patent infarct-related vessel have a very favorable long-term prognosis compared with those who have an occluded coronary artery.1-5 A patent infarct vessel has been associated with not only preservation of cardiac function, but also improved myocardial healing, less infarct expansion, and a reduction in electrical instability.6-9 Although many experimental and observational clinical studies have reinforced the potential merit of a patent infarct-related and to date, subgroup analysis from two large-scale, controlled thrombolytic trials have suggested only a marginal survival benefit.1"12 The results from one of these trials indicated a significantly higher rate of cardiac rupture among late-entry patients treated with streptokinase. 13 Furthermore, several angiographic studies of treatment after 3 hours of chest discomfort suggest a direct relation between duration of symptoms and likelihood of thrombolytic failure.14"5 Thus, although the benefit of late reperfusion strategies has yet to be adequately confirmed, there may be incremental risk of thrombolytic therapy beyond bleeding complications in this group of patients. To explore whether thrombolysis is effective in this setting and the potential mechanism of benefit of late myocardial reperfusion, we performed a randomized, controlled trial of intravenous thrombolysis and, in patients with a documented occluded infarctrelated vessel, coronary angioplasty.
Methods

Patient Selection
Patients with an acute myocardial infarction more than 6 but less than 24 hours after the onset of symptoms were considered for entry into the study. An ECG ST-segment elevation of 1 mm or more in two or more contiguous leads was required. Patients were excluded for the following reasons: 1) age above 75 years; 2) chest pain relieved by nitroglycerin; 3) a history of stroke or recent surgery or trauma; 4) a predisposition to bleeding; 5) previous Q-wave infarction in the distribution of the infarct-related artery; or 6) blood pressure greater than 180/110 mm Hg by two separate measurements. Approval by the institutional review board was granted at each site before enrollment. Recruitment began on April 14, 1988 , and ended on May 5, 1990. 
Study Design
After they gave informed consent, the patients received either intravenous tissue-type plasminogen activator (t-PA) (Genentech, South San Francisco, Calif.) or placebo on a double-blind basis through a separate infusion line with normal saline. The dose of t-PA was 1.0 mg/kg body wt in the first hour, with 10% administered as a bolus and a maximum of 80 mg. In the subsequent hour, 20 mg was given such that the maximal total dose was 100 mg. All patients were treated with a 5,000-unit bolus of heparin at 120 minutes after the study medication was initiated, and a heparin infusion was maintained at 1,000 units/hr, adjusted to keep the partial thromboplastin time at 1.5-2 times the control level for at least 48 hours. Oral aspirin was given at a dose of 325 mg/day. Other medications including /3-blockers, nitrates, angiotensin converting enzyme inhibitors, and calcium channel blockers were not administered unless specifically required to treat myocardial ischemia, hypertension, or supraventricular arrhythmias. At 6-24 hours after the study medication was given, patients were transferred to the cardiac catheterization laboratory at one of the 12 clinical sites. Vascular access was obtained through the femoral or brachial artery. A left ventriculogram was obtained. The infarct-and non-infarct-related coronary arteries were visualized with contrast injections in multiple views, and final patency of the infarct vessel was determined after the fourth injection according to the classification of the Thrombolysis in Myocardial Infarction (TIMI) trial. 15 Patients who had persistent occlusion of the infarctrelated vessel (TIMI grade 0 or 1) were eligible for randomization to coronary angioplasty or no angioplasty. The following findings were grounds for exclusion from randomization: 1) stenosis in the left main coronary artery of more than 50% or its equivalent (275% lesions in the proximal left circumflex and left anterior descending arteries); 2) severe, diffuse, multilesional infarct vessel disease; 3) a small infarct vessel or branch judged to be insignificant; or 4) an unidentifiable infarct vessel. One of a group of consecutively numbered sealed envelopes containing a card generated at the biostatistical core laboratory was pulled for random assignment of the patient to undergo angioplasty at the same sitting or not at all. The time of the angioplasty relative to symptom onset ranged from 7 to 48 hours; the mean time was 25 hours. In patients assigned to angioplasty, only dilatation of the infarct vessel was performed, but if several lesions were present in this artery, they were all approached with a goal of achieving patency and <50% residual stenosis. Two to four inflations, to a maximum of 8-10 atmospheres for a 120second interval, were routinely used. Success was defined as crossing and dilating the lesion with the balloon catheter and achievement of a flow of TIMI grade 2 or 3 at the time of discharge from the laboratory, irrespective of the residual stenosis.
Patients were followed for a 6-month period after entry, and if they gave informed consent, they underwent two follow-up studies. The first was a rest and exercise gated cardiac blood pool scan at 4-6 weeks after infarction. The second study was a repeat cardiac catheterization performed at 4-6 months. All of the radionuclide and angiographic studies were forwarded to the core facilities for independent review.
During follow-up, the endpoint of reocclusion was defined as recurrent total occlusion of the infarctrelated vessel at any time after the patient left the cardiac catheterization laboratory. Patients who developed recurrent ischemia, defined as more than 20 minutes of angina that was not responsive to nitrates and was accompanied by ECG ST-segment elevation, were considered for angioplasty or coronary artery bypass surgery. If a positive exercise test for provocable myocardial ischemia was obtained before hospital discharge or at any time during follow-up, the patient was eligible to be referred for angioplasty or surgical revascularization, irrespective of the initial angioplasty assignment. Congestive heart failure was defined as the need for inotropic and diuretic therapy. Reinfarction was diagnosed by clinical recurrence of chest discomfort associated with an abnormal elevation of the myocardial band isoform of creatine kinase.
Angiographic and Radionuclide Core Laboratories
All cineangiographic films were forwarded to the core laboratory for blinded review, by a single observer, of every ventriculogram as well as evaluation of the patency of the infarct-related vessel (TIMI grades 0-3) and quantification of the residual stenosis by use of an automated edge-detection computer algorithm.16 Out-lines of the cavity of the ventricle at end systole and end diastole were obtained, digitized, and stored in a digital radiographic computer (DPS 4100AC, ADAC Laboratories, Milpitas, Calif.) for subsequent processing. The global ejection fraction and end-systolic and end-diastolic volumes were determined by the area-length method using a calibrated grid and correction for magnification at each clinical site.17 Regional wall motion was determined by the centerline chord method18 for the infarcted and noninfarcted zones and expressed as SD per chord. The intraobserver variability for our laboratory has been previously published. 2 Gated blood pool scans were obtained at rest and with bicycle exercise. Red blood cells were labeled in vivo with 25 mCi of 9'mTc. Standard imaging was performed in anterior, left anterior oblique, and left lateral views, and the data were acquired in frame mode by computer-based ECG gating. The radionuclide ventriculograms were forwarded to the core laboratory for pooling of the data, which were translated into a common file format using a dedicated computer system (Sudbury Systems, New York). The left ventricular ejection fraction at rest and at peak exercise was determined by a varying region on interest approach percent. 19 The data analysis was performed with a Siemens MicroDELTA computer (Siemens Medical Systems, Inc., Hoffman Estates, Ill.) and CDA version 6.0 software (Computer Design & Applications, Inc., Waltham, Mass.). The investigators had no knowledge of the data on left ventricular function or volumes until the study enrollment and data analysis were complete.
Determination of Sample Size
The primary end point for the trial was infarct vessel patency at 6-24 hours after study drug administration. Before the start of the study, it was determined that 200 patients would be required to demonstrate a 30-percentage-point difference in patency between t-PA therapy versus placebo, assuming patency rates of 65% and 35%, respectively (a, 0.01; power, 0.90). As a secondary end point, the 200 patients enrolled would be sufficient to detect a six-point difference in ejection fraction by gated cardiac blood pool scintigraphy (a, 0.01; power, 0.90; SD, 11 ejection fraction points).
For the randomization to angioplasty or no angioplasty, it was calculated that 70 patients would need to be enrolled in order to detect a nine-point difference in ejection fraction by gated cardiac blood pool scintigraphy (a, 0.05; power, 0.90; SD, 11 ejection fraction points). Thus, we anticipated that in the first randomization a total of 200 patients would be required and, assuming a 35% eligibility for angioplasty assignment, there would be an adequate number of patients to assess the effects of angioplasty in the setting of an occluded infarct vessel.
Data Analysis
Computer data entry of the case-report forms and quality control of the data were performed in the biostatistical core unit at Duke University. Quality assurance of the data was performed by a single research nurse's source documentation of every patient's medical chart compared with the case-report form; any discrepancies were verified by the principal investigator 16 t-PA, tissue-type plasminogen activator; MI, myocardial infarction; LAD, left anterior descending; LCx, left circumflex; RCA, right coronary artery; SBP, systolic blood pressure; bpm, beats per minute.
*There were no significant differences in baseline characteristics (p<0.05) except for number of diseased vessels (p=0.023). and nurse coordinator at each clinical site. Data are expressed as mean± 1 SD. Variables that showed distributions (end-systolic and end-diastolic volumes) were described in terms of selected percentiles. Characteristics at baseline and clinical outcomes were tabulated, and treatment groups were compared by the x2 test or Fisher's exact test for discrete variables and the Wilcoxon rank-sum test for continuous characteristics. Within-group comparisons of change from baseline to the 6-month angiographic follow-up were performed using the Wilcoxon signed-rank test. All reported probability values are two-tailed. All endpoints were assessed according to the intention-to-treat principle. We prespecified a subgroup analysis of the data dividing the patients into two groups with respect to duration of symptoms, either 6-12 hours or 12-24 hours. With the two randomizations, study of interaction between the two therapies or control groups was necessary. To evaluate the potential confounding effect of angioplasty on placebo group outcomes, a secondary analysis was performed by deleting the patients who were subsequently randomly assigned to angioplasty.
Results
Baseline Clinical and Angiographic Features
Relevant demographic and baseline characteristics for the patients randomized to t-PA or placebo are summarized in Table 1 . The two groups were balanced for most features with the exception of extent of coronary artery disease. Patients assigned to placebo more frequently had only single-vessel involvement. The subset of patients with occluded infarct vessels who were randomly assigned to coronary angioplasty or no angioplasty were quite similar with respect to baseline demographic and angiographic indices ( Table 2 ). Approximately three fourths of patients who were subject to this secondary randomization had received placebo therapy initially. There were no significant differences in concomitant medications between both groups of randomized patients.
Results of Thrombolytic Intervention
At coronary angiography 17+7 hours from study medication, patients who received t-PA had a significantly higher infarct vessel patency rate. As shown in Figure 1 , the patency rate was 65% versus 27%, respectively, and the difference was less in patients treated after 12 hours of symptoms. Three patients died before cardiac catheterization and were deleted from further analysis of patency status or cavity volumetric data. In two patients in each group, the infarct vessel was not defined because of complex multivessel coronary disease. Ten patients, of whom eight were in the placebo group and two in the t-PA group, were diagnosed as having normal coronary arteries and ruled out for myocardial infarction by enzymatic criteria.
The mortality in the hospital was similar for the two groups (9.4% in patients assigned to thrombolytic ther- apy versus 8.9% in the placebo group). The cumulative 6-month follow-up mortality was 12.5% versus 9.9% (p=0.56). Clinical follow-up to 6 months was complete in all but one patient enrolled. The 6-month reinfarction rate was 3.2% versus 5.0% (p=0.42). Hospital readmission rates were similar (19% versus 14%, respectively). The frequency of coronary artery bypass surgery within the first 6 months was higher in the plasminogen activator group (27% versus 15%, respectively; p=0.042). The use of nonacute angioplasty was similar in the two groups (21% versus 16%, respectively; p=0.33). The cumulative 6-month rate of coronary angioplasty was 32% for the t-PA group and 38% for placebo patients (p=0.40). According to the study design, the chances for placebo group patients to be randomly assigned to coronary angioplasty (or no angioplasty) were substantially greater. Serious bleeding complications were quite infrequent in the trial; there were no intracerebral hemorrhages.
The transfusion requirement for two units or more of blood or packed red cells was 8.3% in thrombolytic patients compared with 9.1% in the placebo group (p=0.85). Excluding transfusion that was related to bypass surgery, the rate was 2.8% versus 3.5%, respectively (p=0.81). The nadir hematocrit for the thrombolytic group was 32.9+±5.8 compared with the placebo group value of 33.7+6.0. Technically inadequate ventriculograms or patient deaths accounted for the decrease in the number of patients with complete data at acute evaluation. At 4-6 weeks, cardiac gated blood pool scintigraphy was available in 129 patients. Of the remaining patients, 19 had died, 24 declined the study, nine had had recent cardiac surgery, and the remaining 16 patients had done their rest or rest and exercise studies, but the data were technically inadequate or could not be pooled because of software incompatibility. The reason for lack of repeat cardiac catheterization at 4-6 months in 72 patients was death in 22, patient refusal in 28, referring physician refusal in four, stroke in two, status after coronary artery bypass surgery in two, lack of infarction or coronary disease at initial presentation in six, and loss of follow-up in eight patients. Of note, baseline demographic characteristics for the 63 thrombolytic and 62 placebo group patients who had late catheterization or did not undergo the procedure were not different ( Table 3 ). As anticipated, there was a higher rate of death and bypass surgery in the patients without 6-month angiographic follow-up. For the thrombolytic therapy randomization, there were no significant differences for ejection fraction, regional wall motion, or cavity volumes at acute study (Table 4) . Similarly, at 4-6-week evaluation, the cardiac gated blood pool scans demonstrated very similar rest and exercise ejection fraction values. At the time of late cardiac catheterization, ejection fraction and regional wall motion of the infarct zone were not different. By analysis of paired acute-phase and 6-month data, there were no differences in ejection fraction ( Table 4 ). The end-systolic and end-diastolic cavity volumes for t-PA group patients tended to be less than placebo group patients, although the between-group differences were not statistically significant. However, in the placebo group there was a significant increase in median enddiastolic volume from acute phase of 127 ml to 159 ml at 6-month follow-up (p=0.006) but no significant in-crease in cavity size for the t-PA group. No significant changes within either group from baseline to 6-month follow-up were observed for end-systolic volumes (Figure 2) . When patients who were assigned to angioplasty were removed from the analysis, these observations were unchanged. The nearly equivalent and relatively high late patency value in the placebo group reflects, in part, the imbalance in assignment of coronary angioplasty in these patients.
Results ofAngioplasty Intervention
The clinical outcomes for the angioplasty and no angioplasty groups were as follows: in-hospital mortality was 8.8% versus 5.4% and cumulative 6-month mortality 8.8% versus 10.8%, respectively; reinfarction to 6 months, 8.8% versus 2.7%; coronary artery bypass surgery to 6 months, 5.9% versus 10.8%; hospital readmission rate, 11.8% versus 5.4%. There were no significant differences in clinical events between the two groups.
As shown in Table 5 , angioplasty was successful in 81% of patients for restoring infarct vessel patency. There were no significant differences in ejection frac- LV, left ventricular; t-PA, tissue-type plasminogen activator; EF, ejection fraction; RWM, regional wall motion; ESV, endsystolic volume; EDV, end-diastolic volume; MUGA, gated cardiac blood pool scan. tion, infarct zone regional wall motion, or intracavitary volumes acutely or at 6 months between the groups. At 4-6-week evaluation, the rest and exercise ejection fraction values by gated cardiac blood pool scintigraphy were superior for the angioplasty group. The improved ejection fraction for the intervention group was not observed at subsequent catheterization. Of particular note, a high rate of subsequent infarct vessel patency was observed for the patients not assigned to angioplasty (38%) that was not significantly different from the angioplasty group (60%). This observation suggests a relatively high frequency (25-35%) of reocclusion in the angioplasty group and late, spontaneous recanalization in the patients not assigned to angioplasty. For the patients who had late cardiac catheterization, there were no differences between the two groups in baseline demographic or angiographic characteristics.
Comparison With Early-Entry Patients
To differentiate between Phases 1-5 of our multicenter experience in reperfusion therapy for acute myocardial infarction, we compared baseline features for patients in the current study with 1,387 patients treated within 6 hours of symptom onset from our data base, which represents cumulative data from previously published reports.2,20-23 These data are summarized in Table 5 and demonstrate a preponderance of female patients, diabetes mellitus, and anterior location of infarction in the late-entry patients. There were no differences in age between the two groups, but only patients less than age 75 were eligible for all of the trials. The early ejection fraction was significantly decreased among the late-entry patients. The tendency for a higher mortality among late-entry patients has similarly been noted in the ISIS-2 trial."
Discussion
The principal finding of this trial is that despite late entry, myocardial reperfusion can be achieved with thrombolysis in 65% of patients and with coronary angioplasty in more than 80% of cases. Although, as anticipated, there was no benefit of global ejection fraction or infarct zone regional wall motion, thrombolytic intervention prevented an increase in end-diastolic volume during the follow-up period, whereas the control group had a 25% increase in this index of cavity size. Angioplasty for patients with an occluded infarct vessel appeared to provide some early benefit of cardiac function when assessed at 1 month, but at subsequent follow-up the improvement did not persist.
Infarct Vessel Patency
The high rate of coronary thrombolytic success achieved in the current study would not have been There was a significant increase in end-diastolic volume for the placebo group from baseline to 6 months and no diastolic cavity size increase in the plasminogen activator (t-PA) group. ... LV, left ventricular; PTCA, percutaneous transluminal coronary angioplasty; EF, ejection fraction; RWM, regional wall motion; ESV, end-systolic volume; EDV, end-diastolic volume; MUGA, gated cardiac blood pool scan. expected given the profile of aged thrombus, which contains crosslinked fibrin, with a clot that is retracted, platelet-rich, containing high levels of t-PA inhibitor, and in a milieu of depleted circulating plasminogen.24-29 The low (27%) infarct vessel patency in the control group of our study, despite the use of intravenous heparin and aspirin, emphasizes the tenacity of these coronary artery thrombi. Previous angiographic trials with intravenous streptokinase or anistreplase have noted a marked decline in infarct vessel patency (assessed at 90 minutes after therapy) in patients treated beyond 6 hours from symptom onset.303' The angiographic data from the current study indicate for the first time in a controlled fashion that an initial high rate of infarct vessel patency can be achieved in patients with protracted symptoms, although there is some falloff in thrombolytic efficacy as time elapses.
Late-Entry Patients
Besides the expected maturation of clot, patients who present after 6 hours from symptom onset may be different in several respects. Pooled data from largescale controlled trials of intravenous thrombolysis that have included late-entry patients32 demonstrate that the control group mortality exceeds 12%, which is higher than the 9-10% untreated mortality in patients presenting within 6 hours. [33] [34] [35] [36] [37] Subgroup analysis of these trials suggests an overall 12% reduction of mortality among late-entry patients but a 25% risk reduction in the early group. 38 The comparison of baseline features for patients in the current trial with our prior experience suggests that patients presenting late are more apt to be women, to be diabetic, and to have a lower initial ejection fraction, all of which denote an increased risk of fatality. In addition to these features, autopsy data from the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)13 and a meta-analysis39 suggest that late-entry patients treated with thrombolysis have an increased risk of cardiac rupture compared with either early or untreated late presenting patients. Thus, as opposed to early patients, those who present late appear to be at higher risk of mortality and less likely to derive benefit from thrombolytic therapy.
Mechanism of Benefit
There are several ongoing large placebo-controlled trials of intravenous thrombolytic therapy in late-entry patients that are designed to determine whether mortality can be reduced. Should benefit be verified, these trials are not focused on the mechanism of benefit. Experimental studies have suggested that late reperfusion prevents infarct expansion, improves left ventricular remodeling, and facilitates myocardial healing.6440
Two recent small randomized trials of t-PA in late-entry patients suggest that intracavitary volumes may be reduced with therapy.41'42 The current study extends these experimental and pilot findings and supports the concept that late reperfusion does not augment cardiac In the current trial, intravenous heparin and oral aspirin were administered to all patients to reduce the likelihood of infarct artery reocclusion.47 A high rate of late reocclusion in thrombolyticor angioplasty-treated patients was documented by repeat catheterization in more than 69% of surviving patients at 6 months. Furthermore, a high frequency of spontaneous recanalization was evident in patients initially occluded who did not undergo angioplasty. This near equilibration of infarct vessel patency status may account for the lack of sustained improvement in cardiac function at 6 months observed in angioplasty-treated patients compared with the observed benefit when assessed at 4-6 weeks. Alternatively, the use of different methods for left ventricular function assessment of lack of exercise provocation may explain the discrepancy. A major difficulty in interpreting data from the current trial relates to the design of sequential pharmacological and mechanical methods for achieving reperfusion. Although these methods alone or in tandem do not appear to establish high rates of sustained patency, should late reperfusion be confirmed as a viable strategy, a major challenge for future therapies will be to achieve this goal. Major obstacles that are present in this setting include more extensive ventricular dysfunction, the aged, relatively resistant coronary artery thrombus, and the appreciable rate of convalescent, spontaneous recanalization.
Limitations
Several shortcomings of our study need to be emphasized. First, the 6-month angiographic follow-up rate of 69% of surviving patients is not ideal. However, there are no differences in baseline characteristics between the two groups of patients who actually had repeat cardiac catheterization. Furthermore, the profiles of the patients who did not have angiographic follow-up also appeared to be quite similar in the two groups. Of note, this was the first of our multicenter trials in which we attempted to systemically repeat angiography at 6 months after myocardial infarction. This proved to be a difficult process, but the follow-up data provided in this report appeared to be representative of the total cohort. Finally, the actual rate is similar to the 1-week angiographic study repeat acquisition in former thrombolytic trials.15,31 Second, there is the potential confounding effect of coronary revascularization after thrombolytic treatment, either by the sequential randomization or by clinically driven reasons such as angina or a positive functional test for myocardial ischemia. In the acute period of initial hospitalization, there was clearly an imbalance of the assignment of angioplasty for the placebo group patients owing to failure to achieve infarct vessel patency via a pharmacological approach. The rates of performing coronary angioplasty or bypass surgery during the follow-up phase were actually low and were evenly distributed between the plasminogen activator and placebo groups. In general, the use of coronary revascularization procedures would have been a more difficult problem had the placebo group patients benefited from the strategy. Our data, on the other hand, suggest that patients receiving t-PA and no angioplasty had a late (6-month) patency result similar to that of the placebo patients who underwent angioplasty. It remains possible that the only late benefit that we demonstrated for the thrombolytic group patients, the lack of increase in end-diastolic volume over time, may not have occurred in the patients assigned to angioplasty because of the further time delay of approximately 20 hours or the potential of p-error for this observation.
In conclusion, this trial demonstrated that it is possible in the majority of late-entry patients to achieve reperfusion with either intravenous thrombolytic therapy or coronary angioplasty. Although the former intervention was associated with favorable effects on left ventricular remodeling, definitive recommendations for applying late reperfusion therapy can be made only after the results of large-scale mortality reduction trials are available.
